Mirum Pharmaceuticals
MIRM
$105.79
+9.59%
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan liver diseases, primarily through its flagship product Livmarli (maralixibat), an orally administered IBAT inhibitor. The company has established itself as a niche player and commercial-stage leader in the treatment of cholestatic pruritus associated with Alagille syndrome and is expanding into other rare liver conditions. The current investor narrative is driven by the company's transition to profitability, evidenced by a positive net income quarter in Q3 2025, and the subsequent market reaction to its Q4 2025 results, which showed a return to a net loss, creating debate around the sustainability of its growth and margin trajectory.…
MIRM
Mirum Pharmaceuticals
$105.79
Investment Opinion: Should I buy MIRM Today?
Rating: Hold. The core thesis is that Mirum is a compelling commercial-stage growth story hampered by an inconsistent path to profitability, creating a high-risk/high-reward profile that currently favors waiting for clearer evidence of sustained margin expansion. This aligns with the analyst community's bullish ratings but tempers the near-term price target optimism with fundamental caution.
Supporting this Hold rating are several data points: robust 49.8% YoY revenue growth, a strong gross margin of 81%, and a healthy cash position of $298M. However, these are counterbalanced by a return to net loss in Q4 (-$5.73M), a high trailing PS ratio of 7.6x (though down from 26.6x), and a sky-high EV/EBITDA of 231.8x. The stock's 143% 1-year gain already prices in significant success, leaving limited margin for error.
The thesis would upgrade to a Buy if the company reports two consecutive quarters of GAAP profitability, signaling sustainable margin discipline, or if the PS ratio contracts below 5x on sustained high growth. It would downgrade to a Sell if revenue growth decelerates below 25% YoY or if cash burn accelerates, threatening the balance sheet. Currently, the stock appears fairly valued relative to its growth profile but overvalued on any metric requiring consistent earnings.
Sign up to view all
MIRM 12-Month Price Forecast
The outlook is bifurcated between stellar top-line execution and a murky bottom-line trajectory. The base case of range-bound trading is most likely, as the market digests whether Q3 2025's profitability was an anomaly or a precursor. The stance would upgrade to bullish on evidence of sustained operating leverage (two profitable quarters) and downgrade to bearish on a material growth slowdown (<30% YoY) or accelerating cash burn. The high short interest adds a layer of potential volatility in either direction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mirum Pharmaceuticals's 12-month outlook, with a consensus price target around $137.53 and implied upside of +30.0% versus the current price.
Average Target
$137.53
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$85 - $138
Analyst target range
Mirum is covered by at least 6 analysts, and institutional sentiment is overwhelmingly bullish, as evidenced by a series of recent 'Buy' or 'Outperform' ratings from firms including TD Cowen, HC Wainwright, and Morgan Stanley throughout early 2026. The consensus revenue estimate for the coming period is $1.60 billion, with a high estimate of $1.69 billion and a low of $1.51 billion, indicating strong expected growth from the current ~$600 million annual run rate. While a specific average price target is not provided in the data, the sustained bullish ratings and high revenue targets imply significant upside potential is expected by the analyst community. The target range derived from revenue estimates suggests a degree of uncertainty, with the high end likely baking in successful commercial execution and label expansions, while the low end may reflect concerns about competition or slower adoption. The pattern of reiterated bullish ratings, even after the Q4 earnings report, signals strong institutional conviction in the long-term story despite near-term profitability fluctuations.
Bulls vs Bears: MIRM Investment Factors
The bull case, anchored in explosive 50% revenue growth, strong analyst backing, and a solid cash position, currently holds stronger evidence. However, the bear case presents a formidable counterpoint centered on the company's inconsistent profitability and the high valuation multiples that depend on flawless execution. The single most important tension in the investment debate is the race between revenue scaling and expense management: Can Mirum leverage its high gross margins to deliver sustained, GAAP profitability before investor patience for losses wears thin? The resolution of this profitability question will be the primary driver of the stock's multiple and direction.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 49.81% year-over-year to $148.93 million, continuing an accelerating trend. This demonstrates strong commercial execution for its rare disease therapies, Livmarli, Cholbam, and Ctexli.
- Strong Analyst Conviction: At least 6 analysts maintain 'Buy' or 'Outperform' ratings, with a consensus revenue estimate of $1.60 billion for the coming period. This implies significant expected growth from the current ~$600 million annual run rate and reflects institutional confidence in the long-term story.
- The company ended Q4 with $298.17 million in cash and generated positive TTM free cash flow of $54.87 million. With a current ratio of 2.67, this provides a substantial runway to fund growth without immediate dilutive financing.
- High Gross Margin Business Model: Gross margin remains consistently high, at 80.97% in Q4 2025. This validates the premium pricing power of its rare disease portfolio and provides a strong foundation for future profitability as operating expenses scale.
Bearish
- Inconsistent Path to Profitability: Despite a profitable Q3 2025 ($2.91M net income), Q4 2025 swung back to a net loss of -$5.73 million. This volatility, with a trailing EPS of -$0.0059, raises questions about the sustainability of its margin trajectory and cost control.
- High Valuation Multiples on Profit Metrics: The stock trades at a trailing PE of -169.7x and an EV/EBITDA of 231.8x, reflecting the lack of consistent earnings. This makes the valuation highly sensitive to any growth deceleration or margin disappointment.
- Sharp Technical Correction from Highs: The stock has corrected approximately -20.55% from its 52-week high of $109.28 to $95.20, breaking its powerful uptrend. This suggests momentum has cooled, potentially due to profit-taking or concerns following the Q4 net loss.
- Elevated Short Interest: A short ratio of 9.04 indicates significant bearish sentiment in the market. This creates a potential overhang and risk of a short squeeze if the stock rallies, but also reflects skepticism about the company's near-term prospects.
MIRM Technical Analysis
The stock is in a sustained long-term uptrend but has recently experienced a sharp correction from its highs. With a 1-year price change of +143.35%, the trend is decisively bullish; however, the current price of $95.20 sits at approximately 80% of its 52-week range ($37.83 to $109.28), indicating a significant pullback from the highs and suggesting the momentum may be cooling after a powerful rally. Recent momentum shows a stark divergence from the long-term trend, with the stock down -3.79% over the past month but still up +9.97% over the past three months. This 1-month decline against a strong yearly gain signals a potential consolidation or profit-taking phase, especially following the sharp drop from above $108 in late February to current levels. Key technical support is at the 52-week low of $37.83, but more immediate support lies in the $86-$90 zone where the stock found a base in March, while resistance is clearly defined at the 52-week high of $109.28. A beta of 0.518 indicates the stock has been significantly less volatile than the broader market, which is unusual for a biotech but may reflect its transition to a commercial-stage entity; however, the recent -20.55% max drawdown highlights that it is not immune to sharp pullbacks.
Beta
0.52
0.52x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$40-$110
Price range past year
Annual Return
+142.1%
Cumulative gain past year
| Period | MIRM Return | S&P 500 |
|---|---|---|
| 1m | +12.3% | +9.5% |
| 3m | +0.3% | +4.1% |
| 6m | +50.9% | +6.0% |
| 1y | +142.1% | +26.7% |
| ytd | +35.5% | +5.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MIRM Fundamental Analysis
Revenue growth is robust but showed volatility in profitability in the most recent quarters. Q4 2025 revenue was $148.93 million, representing a strong 49.81% year-over-year growth, continuing an accelerating trend from prior quarters. The company's sole reported segment, Product revenue, is driving this growth, primarily from its commercialized therapies Livmarli, Cholbam, and Ctexli. Profitability remains inconsistent; while Q3 2025 showed a net income of $2.91 million, Q4 2025 swung back to a net loss of -$5.73 million, though this was a significant improvement from the -$23.79 million loss in Q4 2024. The gross margin remains healthy at 80.97% for Q4, consistent with its high-margin pharmaceutical business model, but operating expenses continue to pressure the bottom line. The balance sheet and cash flow position appear solid, with a current ratio of 2.67 indicating good short-term liquidity, though a debt-to-equity ratio of 1.02 shows a balanced but notable use of leverage. Trailing twelve-month free cash flow is positive at $54.87 million, and the company ended Q4 with $298.17 million in cash, providing a substantial runway to fund operations and growth initiatives without immediate need for dilutive financing.
Quarterly Revenue
$148932000.0B
2025-12
Revenue YoY Growth
+0.49%
YoY Comparison
Gross Margin
+0.80%
Latest Quarter
Free Cash Flow
$54873000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MIRM Overvalued?
Given the company's inconsistent profitability, with a trailing net income of -$0.0059 per share, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 7.61x, while the forward-looking valuation is implied by analyst estimates for revenue of $1.60 billion, suggesting a forward PS significantly lower if those targets are met. Compared to the broader biotechnology industry, a PS ratio around 7-8x is not uncommon, but the key differentiator will be the company's ability to convert high revenue growth into sustained profits. Historically, Mirum's own valuation has compressed from much higher levels; for instance, its PS ratio was 26.62x at the end of Q4 2025 and has since contracted to the current 7.61x. This places the stock near the lower end of its own historical PS band over the past two years, which has ranged from single digits to over 150x during its pre-revenue phase, suggesting the market may be pricing in a more conservative growth outlook or awaiting more consistent profitability.
PE
-169.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -173x~367x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
231.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks stem primarily from the company's unproven path to consistent profitability. While revenue grew 49.8% YoY in Q4, net income swung from a $2.9M profit in Q3 to a $5.7M loss in Q4, highlighting volatile cost control. A debt-to-equity ratio of 1.02 indicates balanced but meaningful leverage. The core risk is that high operating expenses (R&D and SG&A) continue to outpace gross profit growth, delaying the inflection to sustained earnings and forcing a reassessment of its 7.6x PS valuation.
Market & Competitive Risks are dominated by valuation compression. The stock trades at a PS of 7.6x and an EV/EBITDA of 231.8x, premiums justified only by hyper-growth. A beta of 0.52 suggests lower market correlation, but this is a double-edged sword—it may not benefit from broad rallies but remains vulnerable to sector-specific rotations out of high-multiple, pre-profitability biotechs. The primary external threat is any development—competitive, regulatory, or reimbursement-related—that causes revenue growth to decelerate from the current ~50% pace, triggering a severe derating.
The Worst-Case Scenario involves a combination of slowing prescription growth for Livmarli, failed clinical trials for pipeline expansions, and persistent operating losses. This could lead to a breach of debt covenants, necessitating dilutive equity financing. Quantifying the downside, a return to the 52-week low of $37.83 would represent a -60% loss from the current $95.20. A more realistic bear-case target, aligning with a significant growth derating, could be in the $50-$60 range, implying a -35% to -47% downside from current levels.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Inability to translate 80% gross margins into consistent net income, as seen in the swing from profit in Q3 to loss in Q4. 2) Growth Execution Risk: Revenue growth decelerating from the current ~50% pace, which would crush its premium valuation. 3) Financing Risk: Although cash is strong now ($298M), persistent losses could eventually necessitate dilutive equity financing. 4) Competitive/Regulatory Risk: New treatments or regulatory setbacks for its core products in rare disease markets.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $95 and $110, as strong revenue growth continues but profitability remains uneven. The Bull Case (30% probability) targets $115-$130 on sustained profitability and upside to revenue estimates. The Bear Case (20% probability) warns of a drop to $60-$85 if growth slows and losses mount. The Base Case is most likely, anchored by the analyst consensus for $1.6B in revenue, but the stock's direction hinges overwhelmingly on its next few quarterly earnings reports.
MIRM's valuation is context-dependent. On a Price-to-Sales basis at 7.6x, it is in line with many commercial-stage biotechs, and notably below its own historical high of over 150x. However, on earnings-based metrics (PE of -169.7x), it is clearly overvalued, as the market is paying for future profit potential that has not yet materialized. Relative to its explosive growth, the current PS may be fair, but it is absolutely overvalued on current earnings. The valuation implies the market expects rapid revenue scaling to soon translate into durable, high-margin profits.
MIRM is a speculative buy for investors comfortable with high risk. The 49.8% revenue growth and $1.6B analyst revenue target suggest significant upside, but the inconsistent profitability (Q4 net loss of -$5.73M) and high valuation multiples (PS 7.6x, EV/EBITDA 231.8x) present substantial risk. It could be a good buy for growth investors who believe the company will soon achieve sustained GAAP profits, but a poor choice for conservative investors seeking stability or income. The high short ratio of 9.04 indicates significant market skepticism to overcome.
MIRM is suitable primarily for long-term investors with a minimum 2-3 year horizon. While the stock has shown high volatility (20.55% max drawdown), its low beta of 0.52 suggests its moves are driven by company-specific execution, not short-term market swings. The investment thesis revolves around the multi-year commercialization and pipeline expansion of its rare disease portfolio, not quick trades. Short-term traders face significant risk from earnings volatility and the high short interest. Long-term holders are betting on the company's ability to grow into its valuation and achieve sustainable profitability.
